Journal
ONCOTARGET
Volume 7, Issue 3, Pages 3171-3185Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.6419
Keywords
tigecycline; melanoma; p21(CIP1/Waf1); cell growth and proliferation; cell migration and invasion
Categories
Funding
- National Basic Research Program of China [2012cb114603]
- National Natural Science Foundation of China [81201551, 31172268]
- Research Fund for the Doctoral Program of Higher Education of China [20130182110003]
- Natural Science Foundation of Chongqing [cstc2013jcyjys0007]
Ask authors/readers for more resources
Antibiotics are common durgs with low toxicity but high effectiveness. They have been suggested to be drug candidates for cancer therapy in recent years. Here, we tried to investigate the antitumour effect of tigecycline on malignant melanoma. We showed that tigecycline dramatically inhibited cell proliferation and induced cell cycle arrest at G0/G1 phase. At the same time, tigecycline suppressed cell invasion and migration through preventing epithelial-mesenchymal transition (EMT) process. In addition, tigecycline also significantly blocked tumor growth in vivo. Expression of cell cycle-related proteins were investigated and resulted in downregulation of G1/S checkpoint proteins, such as CDK2 and Cyclin E. However, cyclin-dependent kinase inhibitor 1 (CDKN1A, p21(CIP1/Waf1)) was downregulated after tigecycline treatment, which was not conformed to its conventional function. To explain this, we overexpressed p21 in melanoma cells. We found that p21 overexpression significantly rescued tigecycline-induced cell proliferation inhibition as well as migration and invasion suppression. Taken together, our results revealed that the essential role of p21 in the inhibitory effect of tigecycline on proliferation, migration and invasion of melanoma. Tigecycline might act as a candidate therapeutic drug for treatment of patients suffering from malignant melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available